Comparative Pharmacology
Head-to-head clinical analysis: LINACLOTIDE versus LINZESS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LINACLOTIDE versus LINZESS.
LINACLOTIDE vs LINZESS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Agonist of guanylate cyclase-C (GC-C) receptor on luminal surface of intestinal epithelial cells, increasing cyclic guanosine monophosphate (cGMP) levels, which activates CFTR ion channel, increasing chloride and water secretion into intestinal lumen, accelerating colonic transit and reducing visceral pain.
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
145 mcg orally once daily, at least 30 minutes before the first meal of the day.
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
None Documented
None Documented
Approximately 9–10 hours (terminal half-life in plasma), supporting once-daily dosing.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Primarily fecal as intact peptide (95%); renal excretion of absorbed drug is minimal (<5%).
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
Category C
Category C
Guanylate Cyclase-C Agonist
Guanylate Cyclase-C Agonist